Ubiquitination is associated with lysosomal degradation of cell surface‐resident ATP‐binding cassette transporter A1 (ABCA1) through the endosomal sorting complex required for transport (ESCRT) pathway

Tadahaya Mizuno, Hisamitsu Hayashi, Sotaro Naoi, Yuichi Sugiyama – 21 April 2011 – ATP‐binding cassette transporter A1 (ABCA1) plays an essential role in the biogenesis of high‐density lipoprotein in liver and in the prevention of foam cell formation in macrophages by mediating the efflux of cellular cholesterol and phospholipids to apolipoprotein A‐I (apoA‐I). Our current study investigated the mechanism of degradation of cell surface‐resident ABCA1, focusing on ubiquitination.

Mitochondria‐targeted ubiquinone (MitoQ) decreases ethanol‐dependent micro and macro hepatosteatosis

Balu K. Chacko, Anup Srivastava, Michelle S. Johnson, Gloria A. Benavides, Mi Jung Chang, Yaozu Ye, Nirag Jhala, Michael P. Murphy, Balaraman Kalyanaraman, Victor M. Darley‐Usmar – 21 April 2011 – Chronic alcohol‐induced liver disease results in inflammation, steatosis, and increased oxidative and nitrosative damage to the mitochondrion. We hypothesized that targeting an antioxidant to the mitochondria would prevent oxidative damage and attenuate the steatosis associated with alcoholic liver disease.

Endpoints and clinical trial design for nonalcoholic steatohepatitis

Arun J. Sanyal, Elizabeth M. Brunt, David E. Kleiner, Kris V. Kowdley, Naga Chalasani, Joel E. Lavine, Vlad Ratziu, Arthur McCullough – 21 April 2011 – Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver‐related mortality and cardiovascular disease. At present, a liver biopsy is the only generally acceptable method for the diagnosis of NASH and assessment of its progression toward cirrhosis.

Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta‐analysis of controlled studies

Armin D. Goralczyk, Nicola Hauke, Narin Bari, Tung Y. Tsui, Thomas Lorf, Aiman Obed – 21 April 2011 – Interleukin 2 receptor antagonists (IL‐2Ra) are frequently used as induction therapy in liver transplant recipients to decrease the risk of acute rejection while allowing the reduction of concomitant immunosuppression. We conducted a systematic review of prospective, controlled studies to test the hypothesis that the use of IL‐2Ra is associated with a decrease in acute rejection and/or a decrease in the side effects of concomitant medication.

Reply:

Josep Maria Orellana‐Gavaldà, Laura Herrero, Maria Ida Malandrino, Guillermina Asins, Fausto G. Hegardt, Dolores Serra – 21 April 2011

Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial‐to‐mesenchymal transition

Kit‐Ying Chung, Ibis K.‐C. Cheng, Arthur K.‐K. Ching, Jian‐Hong Chu, Paul B.‐S. Lai, Nathalie Wong – 21 April 2011 – Genomic amplification of regional chromosome 8q24 is a common event in human cancers. In hepatocellular carcinoma (HCC), a highly aggressive malignancy that is rapidly fatal, recurrent 8q24 gains can be detected in >50% of cases. In this study, attempts to resolve the 8q24 region by way of array comparative genomic hybridization for affected genes in HCC revealed distinctive gains of block of proliferation 1 (BOP1).

Subscribe to